George Matcham
Direktor/Vorstandsmitglied bei INSTIL BIO, INC.
Vermögen: 419 269 $ am 31.05.2024
Aktive Positionen von George Matcham
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| INSTIL BIO, INC. | Direktor/Vorstandsmitglied | 01.09.2018 | - |
| Independent Dir/Board Member | 01.09.2018 | - |
Karriereverlauf von George Matcham
Ehemalige bekannte Positionen von George Matcham
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| CHIMERIC THERAPEUTICS LIMITED | Direktor/Vorstandsmitglied | 05.07.2021 | 03.08.2023 |
| CELGENE | Corporate Officer/Principal | 01.05.2013 | 01.06.2018 |
Celgene Cellular Therapeutics
 Celgene Cellular Therapeutics Pharmaceuticals: MajorHealth Technology Part of Bristol Myers Squibb Co., Celgene Cellular Therapeutics develops human pharmaceuticals. The company is based in Warren, NJ. The company was founded by Robert Joseph Hariri Gordon. | Geschäftsführer | - | - |
Ausbildung von George Matcham
| University of Cardiff | Doctorate Degree |
| University of Cambridge | Graduate Degree |
Statistik
International
| Vereinigte Staaten | 4 |
| Vereinigtes Königreich | 3 |
| Australien | 2 |
Operativ
| Director/Board Member | 2 |
| Independent Dir/Board Member | 1 |
| Chief Operating Officer | 1 |
Sektoral
| Health Technology | 5 |
| Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| INSTIL BIO, INC. | Health Technology |
| CHIMERIC THERAPEUTICS LIMITED | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Celgene Cellular Therapeutics
Celgene Cellular Therapeutics Pharmaceuticals: MajorHealth Technology Part of Bristol Myers Squibb Co., Celgene Cellular Therapeutics develops human pharmaceuticals. The company is based in Warren, NJ. The company was founded by Robert Joseph Hariri Gordon. | Health Technology |
Celgene Corp.
 Celgene Corp. BiotechnologyHealth Technology Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include Revlimid, Pomalyst, Imnovid, Otezla, Abraxane, and Vidaza. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ. | Health Technology |
- Börse
- Insiders
- George Matcham
- Erfahrung
